TG Therapeutics sees FY26 revenue $875M-$900M, consensus $895.63M

The company said, “Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, and approximately $100 million in expenses associated with the subcutaneous Briumvi inventory build and secondary manufacturer start-up costs”